Abstract: The present invention relates to microorganisms for use in the treatment and/or prevention of skin conditions by topical application. In particular, the microorganisms are for use in the treatment and/or prevention of loss of skin barrier function, inflammatory conditions and/or growth of pathogenic microorganism. The invention further relates to pharmaceutical or cosmetic compositions or products comprising the microorganisms Provided is also a cosmetic use of the microorganisms or compositions for application on the skin and a cosmetic method, in particular to improve the appearance of the skin.

Abstract: The invention relates to the use of at least one strain of Lactobacillus plantarum in a method for increasing the numbers of Oscillospira spp. in a subject and preferably maintaining the increased numbers, the method comprising administering the at least one strain of Lactobacillus plantarum to the subject. Preferably, the uses and methods of the invention are used to treat a subject with dysbiosis of Oscillospira spp., especially those suffering from an associated disorder, syndrome or disease.

Abstract: The invention provides a microbial composition in the form of a powder for oral administration comprising or consisting of: (i) micro-organism, preferably probiotic bacteria; (ii) sugar alcohol, such as Erythritol and Xylitol; (iii) moisture absorbent fibre, such as inulin; (iv) a flow agent, such a silicon dioxide optionally; (v) a flavorant; and/or optionally (vi) a bulking agent, such as maltodextrin. The compositions display good storage stability, fast-melt and sensory properties. They are preferably packaged in a single dose in a sealed stick pack aluminium container.

Abstract: The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis. In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.

Abstract: The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gut-mucosa.

Abstract: The present invention relates to a certain microorganism for altering the composition of oral biofilms, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. In particular, the present invention relates to a microorganism for use as a probiotic agent for altering the bacterial composition of oral biofilms derived from saliva, preferably for reducing the proportions of Gram-negative anaerobic genera and/or increasing the proportions of aerobic or facultatively anaerobic genera. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising the microorganism as probiotic agents as well as a method of production thereof.

Abstract: The present invention relates to at least one probiotic strain of Lactobacillus for use in a subject for the prevention and/or treatment of celiac disease autoimmunity (CDA), or for use in the prevention and/or treatment of celiac disease (CD). A preferred composition for use according to the invention is a composition comprising a combination of Lactobacillus paracasei and Lactobacillus plantarum, especially L. paracasei 8700:2 (DSM 13434) in combination with L. plantarum HEAL 9 (DSM 15312).

Abstract: The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. In particular, the present invention relates to microorganisms or mixtures thereof for use as an anti-inflammatory agent in the oral cavity for reducing or inhibiting the release of certain inflammatory factors. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the microorganisms as probiotic agents as well as a method of production thereof.

Abstract: The present invention relates to a novel bacterial strain, L. plantarum GOS 42 (DSM 32131), isolated preparations and compositions thereof; and their use in medicine, especially in the treatment and/or prevention of inflammation.

Abstract: The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.

Abstract: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a part thereof, for the preparation of a composition for increasing the absorption of at least one kind of metal/metal ion in a mammal, preferably a human.

Abstract: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum '299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a part thereof, for the preparation of a composition for increasing the absorption of at least one kind of metal/metal ion in a mammal, preferably a human.

Abstract: The present invention relates to a method for modifying polyphenol containing plant material(s), wherein said method comprises: mixing at least one polyphenol containing material and at least one solvent to provide a mixture; heating the mixture to eliminate bacterial species present to provide a heated mixture; adding at least one polyphenol modifying strain of lactic acid bacteria and optionally at least one protein source, in optional order or simultaneously, to the heated mixture to provide a fermentation mixture; and subjecting the fermentation mixture to conditions suitable for fermentation of the fermentation mixture to provide a mixture of modified polyphenol containing plant material(s); and optionally eliminating the polyphenol modifying strain of lactic acid bacteria to provide a mixture of modified polyphenol containing plant material(s) free from living lactic acid bacteria.

Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.

Abstract: New strains of Lactobacillus paracasei which can be used as probiotics in dairy products and which are characterized in surviving the gastrointestinal passage and giving a palatable cheese product when used as an adjunct in cheese manufacturing. The invention especially refers to the new strains Lactobacillus paracasei 8700:2, DSM 13434, and Lactobacillus paracasei 02A, DSM 13432. The invention also refers to dairy food products, such as cheese, containing said strains.

Abstract: The present invention relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a pharmaceutical composition for the treatment and/or prevention of a virus infection.

Abstract: A probiotic fruit juice drink consisting of at least one species of probiotic bacteria chosen from Lactobacillus and at least one gas formation reducer chosen from acerola, pomegranate, cranberry, arqnia, blackcurrant, buckthorn or elderberry and any combination thereof and a primary fruit juice chosen from a citrus fruit juice or an pip fruit juice. The probiotic juice drink contains optionally a secondary fruit juice and optionally water.

Abstract: Use of one strain of Lactobacillus plantarum for the manufacture of a composition for increasing the diversity of the gastrointestinal tract by administration of said strain to an individual with a view to producing an increased diversity index compared to placebo is disclosed, as well as use of one strain of Lactobacillus plantarum for the manufacture of a composition for prophylactic treatment of a healthy individual against developing a low bacterial diversity (LBD); of an individual having LBD against developing one or more physiologically disturbed conditions, large intestine bacterial overgrowth (LIBO) or small intestine bacterial overgrowth (SIBO); and of an individual having LIBO or SIBO against developing one or more physiologically disturbed conditions, and a method for increasing said diversity.

Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.

Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.